<DOC>
	<DOCNO>NCT02753218</DOCNO>
	<brief_summary>The purpose study investigate effect multiple oral dos LEO 32731 pharmacokinetics single oral dose cytochrome P450 3A substrate midazolam healthy male subject .</brief_summary>
	<brief_title>A Phase I Study With LEO 32731 Midazolam Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Subjects , prior studyrelated activity , give write informed consent participate study abide study restriction . caucasian 18 59 year age , inclusive Subjects body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive . Subjects must good health Male subject willing , whose partner willing , use appropriate contraception ( condom spermicidal foam/gel/film/cream/suppository ) , willing refrain donate sperm time first dose 3 month final dosing occasion . Male subject whose partner child bear potential must also agree use additional highly effective method contraception Subjects receive prescribed systemic topical medication within 14 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration midazolam . Subjects received medication , include St John 's Wort ( dietary restriction ) , know chronically alter drug absorption elimination process ( change enzyme level ) within 30 day first dose administration midazolam . Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) market drug within past 3 month prior first dose occasion . Subjects donate blood , plasma platelet 3 month prior screen make donation 2 occasion within 12 month precede first dose administration midazolam . Subjects significant history drug allergy determine Investigator . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . Subjects supine blood pressure supine pulse rate screen high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 45 bpm , respectively . Subjects consume 28 unit alcohol per week . Subjects significant history alcoholism drug/chemical abuse determine Investigator . Subjects positive urine drug abuse screen alcohol breath test result screen first admission . Subjects smoke smoke 3 month prior first dose administration . Subjects , history , clinically significant neurological , gastrointestinal ( GI ) , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , dermatological major disorder determine Investigator . Subjects clinically significant illness within 4 week start dose administration determine Investigator . Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test human immunodeficiency virus ( HIV ) antibody . Active tuberculosis history incompletely treated tuberculosis , base medical history medical report , tuberculosis test screening . Subjects , opinion General Practitioner Investigator , participate study , include subject suspect whatever reason able comply requirement protocol . Subjects abnormality 12lead ECG , opinion Investigator , increase risk participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>